Formulation d’un médicament traditionnel amélioré à base de Kalanchoe crenata (Andr) haw (notice n° 654012)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05174cam a2200385 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121190125.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Djoko, Ernest |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Formulation d’un médicament traditionnel amélioré à base de Kalanchoe crenata (Andr) haw |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2016.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 35 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Kalanchoe crenata est une plante de la famille des Crassulaceae très utilisée en médecine traditionnelle africaine. Dans la région Ouest du Cameroun, Kalanchoe crenata est très utilisée avec satisfaction dans le traitement des otites et comme cicatrisant du nombril des nouveaux nés. Compte tenu des difficultés d’approvisionnement de la plante en saison sèche et dans les zones arides, ce travail s’est donné pour objectif de mettre au point un médicament traditionnel amélioré afin de rationaliser l’utilisation de Kalanchoe crenata sous une forme galénique à biodisponibilité améliorée et disponible en toute saison. La plante, qui pousse facilement autour des habitations (plante sauvage) a été récoltée à Bangangté durant les mois d’août et septembre 2012 puis identifiée à l’Herbier National du Cameroun. Les feuilles ont ensuite été nettoyées, lavées, ramollies à la flamme et broyées. Le jus brut obtenu a été filtré sur papier Whatman n° 3 puis lyophilisé, donnant une poudre à reconstituer dans de l’eau purifiée au moment de l’utilisation.Le dosage des polyphénols totaux par spectrophotométrie, méthode de Folin-Ciocalteu a révélé que le lyophilisat titrait 6,33 μg équivalent acide gallique (EAG) par mg.La concentration minimale inhibitrice (CMI) a été déterminée pour quelques germes habituellement mis en cause dans les otites : 50 μg EAG par ml pour Citrobacter fruendi, 100 μg EAG par ml pour Staphylococcus aureus, 200 μg EAG par ml pour Klessiella pneumoniae, Proteus mirabilis et Escherichia coli. Pour Pseudomonas aeruginosa la CMI de la poudre était de 400 μg EAG par ml.La poudre a donc été conditionnée pour qu’après reconstitution, la solution puisse titrer 400 μg EAG par ml en référence à la CMI de Pseudomonas aeruginosa.La solution reconstituée s’est révélée chimiquement stable et active sur les germes plus de 20 jours après reconstitution.La poudre soumise à une température de 40 °C et à la lumière pendant un mois, s’est révélée stable. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The objective of this study was to perform an improved traditional medicine based on Kalanchoe crenata, a local plant active on otitis. The plant was harvested in Bangangté (West Cameroon) during the months of August and September, 2012. It has been identified in the National Herbarium of Cameroon. The leaves were torn out, washed, softened in the flame, crushed and filtered, before the completion in our dosage form. This dosage form is a powder obtained by lyophilization of raw juice. The activity test carried out with the juice of strains of Staphylococcus aureus, Klessiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Escherichia coli, Citrobacter fruendi showed no activity against these germs, but when concentrate to 50%, it showed an activity against Staphylococcus aureus. This led us to choose a more concentrated drug dosage form: i.e. powder to be reconstituted in an appropriate solvent at the time of use. Assay of total polyphenols was performed spectrophotometrically using the Folin-Ciocalteu reagent. By this assay, we determined that our dry headlined 6.33 μg gallic acid equivalent per mg of powder. The activity test showed the minimum inhibitory concentrations of 50 micrograms of gallic acid equivalents per ml for Citrobacter fruendi, 100 micrograms per ml for Staphylococcus aureus, 200 micrograms per ml for Klessiella pneumoniae, Proteus mirabilis and Escherichia coli. For Pseudomonas aeruginosa the MIC was 400 micrograms per ml GAE. The drug product has been packaged to contain GAE 400 micrograms per ml after reconstitution. The suspension obtained after reconstitution in purified water retained its antimicrobial activity. The analytical assay showed that polyphenol content remained unchanged 20 days after reconstitution. The preliminary stability test conducted showed that the drug product was stable to light, at a temperature of 40°C in the dark for more than one month storage. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Médicament traditionnel amélioré |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Antibactérien |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Kalanchoe crenata |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Formulation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Otite |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Efficacy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Methodology |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Cost-efficacy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Validation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Clinical research |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Surveillance |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Innocuity |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Non-pharmacological intervention |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Tchantchou, Corine |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kanmangné, François-Marie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Foutse, Yimta |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fotsing Kwetche, Pierre |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Wouessidjewe, Denis |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hegel | 4 | 4 | 2016-11-01 | p. 380-387 | 2269-0530 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hegel-2016-4-page-380?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hegel-2016-4-page-380?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux